Integra has received 510(k) clearance from the FDA to market flowable wound matrix in the US.
Tom Tarca, vice president of marketing for the extremity reconstruction business, Integra, said: “We are excited to utilize our extensive collagen technology to design, engineer and manufacture a new wound matrix, which specifically fills a clinical need in the treatment of wounds.”